Endoscopic and Pharmacologic Treatment of Obesity in Patients With Hereditary Polyposis Syndromes-Reference-Cited by-同舟云学术

Endoscopic and Pharmacologic Treatment of Obesity in Patients With Hereditary Polyposis Syndromes

Published:2024-09 Issue:9 Volume:11 Page:e01514
ISSN:2326-3253
Container-title:ACG Case Reports Journal
language:en
Short-container-title:ACG Case Rep J

Author:

Iyer Meghana¹,Firkins Stephen A.²,Patel Roma²,Flora Bailey²,Staneff Erika²,Simons-Linares Roberto²

Affiliation:

1. Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Foundation, Cleveland, OH

2. Digestive Disease and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH

Abstract

ABSTRACT Patients with hereditary polyposis syndromes (HPS) are among the highest risk of multiple types of cancer. This risk is further magnified by comorbid obesity; however, HPS present unique risks for bariatric surgery. The advent of endoscopic bariatric and metabolic therapies along with advancements in the realm of antiobesity medications provides potential weight loss alternatives in this vulnerable population. We present 2 cases of patients with obesity and HPS successfully treated with intragastric balloons in combination with antiobesity medications.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference8 articles.

1. Impact of bariatric surgery on cancer risk reduction;Bruno;Ann Transl Med.,2020

2. Unique challenges of risk-reducing surgery for hereditary diffuse gastric cancer syndrome: A narrative review;Gallanis;Eur J Cancer Prev.,2023

3. The genetics of obesity: From discovery to biology;Loos;Nat Rev Genet.,2022

4. Obesity and cancer: A current overview of epidemiology, pathogenesis, outcomes, and management;Pati;Cancers (Basel).,2023

5. Bariatric surgery and the risk of cancer in a large multisite cohort;Schauer;Ann Surg.,2019